Scleroderma and Gleevec treatment

ChEBI2009-03-31 更新2026-07-21 收录

下载链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-11130

下载链接

链接失效反馈

官方服务：

资源简介：

Scleroderma and Gleevec treatment

创建时间：

2009-03-31

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

The primary objective of this trial is to explore the overall objective best response rate and the rate of non-progression at 16 weeks of sequential, alternating weekly administration of BIBF 1120 and

NIAID Data Ecosystem60

Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancer

Interventions: bi weekly cetuximab Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized

NIAID Data Ecosystem60

Data_Sheet_1_Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation.pdf

Pancreatic cancer is one of the most leading causes of cancer death worldwide. The rapid development of next-generation sequencing (NGS) and precision medicine promote us to seek potential targets for

NIAID Data Ecosystem30

Biomarker - Panitumumab Response With KRAS Wild Type MCC

This is an exploratory study in which all eligible subjects are given Panitumumab according to the dose and schedule approved by Health Canada. The purpose of this research study is to determine wheth

NIAID Data Ecosystem60

RNA-Seq analysis of skin from bleomycin induced scleroderma murine models treated with EHP-101 or Ajulemic acid. RNA-Seq analysis of skin from bleomycin induced scleroderma murine models treated with EHP-101 or Ajulemic acid

Several lines of evidence have shown that the endocannabinoid system (ECS) may play a role in the pathophysiology of systemic sclerosis (SSc). Thereby, structurally different dual PPARγ/CB2 agonists s

NIAID Data Ecosystem40